Adjuvant Endocrine Tx Adherence Disparity Due to Varying Costs

Share this content:
Adjuvant Endocrine Tx Adherence Disparity Due to Varying Costs
Adjuvant Endocrine Tx Adherence Disparity Due to Varying Costs

FRIDAY, Nov. 4, 2016 (HealthDay News) -- For women with hormone receptor-positive breast cancer, adherence to adjuvant endocrine therapy (AET) is mainly due to demographic variables and out-of-pocket medication costs, according to a study published online Oct. 28 in the Journal of Clinical Oncology.

Albert J. Farias, Ph.D., and Xianglin L. Du, M.D., Ph.D., from the University of Texas Health Science Center at Houston, conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results-Medicare linked database to identify patients aged ≥65 years with hormone receptor-positive breast cancer who were enrolled in Medicare Part D from 2007 to 2009. Using the medication possession ratio (≥80 percent) during the 12-month period, the authors assessed adherence to tamoxifen, aromatase inhibitors (AIs), and overall AET.

The researchers found that 36.8 percent of the 8,688 patients were nonadherent to AET. The adjusted odds of adherence were lower with out-of-pocket costs for AET medication for all four cost categories compared with the lowest category of ≤$2.65. At initiation, Hispanics had higher odds of adherence to any AET and blacks had higher odds of adherence to AIs, both compared with non-Hispanic whites (odds ratios, 1.30 and 1.27, respectively). The correlations were no longer significant after adjustment for copayments, poverty status, and comorbidities. After adjustment for socioeconomic, clinical, and prognostic factors, blacks had significantly lower adjusted odds of adherence than non-Hispanic whites when they initiated AET therapy with tamoxifen (odds ratio, 0.54).

"Racial/ethnic disparities in AET adherence were largely explained by women's differences in socioeconomic status and out-of-pocket medication costs," the authors write.

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Recent Decline in Prescription Opioid Use Among U.S. Teens

Recent Decline in Prescription Opioid Use Among U.S. ...

Lifetime prevalence of use peaked in 1989, 2002, and remained stable until decline in 2013 to 2015

Treatment Seeking Low Among Teens With Eating Disorders

Treatment Seeking Low Among Teens With Eating Disorders

Those with counter-stereotypic presentation even less likely to seek treatment

Optical Clearing Agent Ups No. of Laser Passes in Tattoo Removal

Optical Clearing Agent Ups No. of Laser Passes ...

Findings based on number of laser passes during a five-minute tattoo removal session

is free, fast, and customized just for you!

Already a member?

Sign In Now »